Change Agents Corporation names Eric Weisblum independent director

Change Agents Corporation, trading as CHGA on The Nasdaq Capital Market, said that on October 14, 2026, it appointed Eric Weisblum as an independent director on the company's board of directors, effective October 12, 2026.¹ Weisblum will serve on each of the Audit, Compensation and Nominating and Corporate Governance Committees.¹

The company described Weisblum as bringing decades of investment banking, capital markets and public company management experience.¹ Since 2020 he has been Chief Executive Officer of Silo Pharma Inc, a biopharmaceutical company that he founded.¹ Before that, he worked as a private investor, board member, and advisor to several companies.¹ The filing noted his experience in both licensing therapeutic assets and assisting in their development,¹ along with nearly 20 years of experience structuring and trading financial instruments.¹

Weisblum's background also includes work as a registered representative with Domestic Securities, a New Jersey-based broker-dealer,¹ where he held several securities industry licenses, including the Series 7, Series 63 and Series 55 registrations. Earlier in his career, from 1993 to 2002, he worked in structured finance at M.H. Meyerson & Co. Inc., a publicly-traded registered investment bank, where he originated, structured, traded and placed structured financing transactions.¹ He holds a bachelor's degree from the University of Hartford's Barney School of Business.

The company said there is no arrangement or understanding between Weisblum and any other person, other than the company's directors acting in that capacity, under which he was selected as a director.¹ It also said Weisblum is not related by blood, marriage or adoption to any director or executive officer,¹ and that it is not aware of any related-party transaction involving Weisblum requiring disclosure under SEC rules.